臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"peng c y"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 86-110 / 360 (共15页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-09-04T06:11:15Z	Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues	Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:14Z	A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection	JIA-HORNG KAO; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L.
臺大學術典藏	2021-09-04T06:11:14Z	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus	Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:11Z	All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study	JIA-HORNG KAO; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S.
臺大學術典藏	2021-09-04T06:11:08Z	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients	Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏	2021-09-04T06:10:54Z	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients	Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; JIA-HORNG KAO; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; JIA-HORNG KAO; Yu M.-L.; Chuang W.-L.; Chen C.-J.
臺大學術典藏	2021-09-04T05:17:13Z	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1	JIA-HORNG KAO; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M.
臺大學術典藏	2021-09-04T05:17:05Z	Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B	Hsu C.-W.; Su W.-W.; Lee C.-M.; Peng C.-Y.; Chuang W.-L.; JIA-HORNG KAO; Chu H.-C.; Huang Y.-H.; Chien R.-N.; Liaw Y.-F.
臺大學術典藏	2021-09-04T05:17:04Z	Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study	JIA-HORNG KAO; Yu M.-L.; Chen C.-Y.; Peng C.-Y.; Chen M.-Y.; Tang H.; Chen Q.; Wu J.J.
臺大學術典藏	2021-09-04T05:16:59Z	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan	Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:58Z	A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment	Liu Y.-T.; Tseng T.-C.; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO; Huang L.-R.
臺大學術典藏	2021-09-04T05:16:57Z	Taiwan consensus statement on the management of chronic hepatitis B	Chien R.-N.; JIA-HORNG KAO; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F.
臺大學術典藏	2021-09-04T05:16:56Z	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: A systematic review and meta-analysis of individual participant data	Pavlovic V.; Yang L.; Chan H.L.-Y.; Hou J.; Janssen H.L.; JIA-HORNG KAO; Lampertico P.; Peng C.-Y.; Piratvisuth T.; Thompson A.J.; Wedemeyer H.; Wei L.; Wat C.
臺大學術典藏	2021-09-04T05:16:55Z	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions	Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏	2021-09-04T05:16:51Z	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study	Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:46Z	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis	Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:43Z	Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy	Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; Su T.-H.; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; JIA-HORNG KAO; Yuen M.-F.; Yu M.-L.; Nguyen M.H.
臺大學術典藏	2021-09-04T05:16:42Z	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions	Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO; Hsu S.-J.; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L.
臺大學術典藏	2021-09-04T05:16:42Z	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment	Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:41Z	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis	Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:39Z	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy	Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:37Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment	Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:36Z	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO; Chuang W.-L.
臺大學術典藏	2021-09-04T05:16:34Z	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations	Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO; Chuang W.-L.
臺大學術典藏	2021-09-04T05:16:31Z	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)	Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO; Liu C.-J.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L.

显示项目 86-110 / 360 (共15页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51741031 在线人数 : 898 教育部委托研究计画计画执行:国立台湾大学图书馆